A new target for immuno-oncology therapies

November 16, 2015

By studying a type of immune cells, a team of researchers at the IRCM led by André Veillette, MD, identified the mechanism of action for a new target for novel immune-oncology treatments. Their discovery is published today in the print edition of the scientific journal the Journal of Experimental Medicine.

The researchers study natural killer (NK) cells, which are crucial to the immune system and protect the body by destroying . The team is more specifically interested in a protein called DNAM-1 that plays a key role in the elimination of cancer cells.

"We discovered the mechanism by which the DNAM-1 protein stimulates the function of NK cells and, thus, increases their capacity to eliminate cancer cells," says Dr. Veillette, Director of the Molecular Oncology research unit at the IRCM.

The DNAM-1 protein is a receptor located at the surface of NK cells. It competes with other receptors that also want to interact with cancer cells, such as the TIGIT receptor that, on the contrary, reduces the efficiency of NK cells.

"When the TIGIT receptor interacts with an infected cell, it prevents its interaction with the DNAM-1 protein, which, as a result, suppresses the function of NK cells and slows the immune system," explains Dr. Veillette.

Recent discoveries have led to the development of several immuno-oncology treatments (or cancer immunotherapy), which use antibodies to improve the immune system's natural function. Some of these antibodies, namely anti-CTLA-4 or anti-PD-1 antibodies, have already shown lasting benefits for many cancer patients.

"Our results reveal how antibodies against TIGIT could become new therapies in immune-oncology," adds Dr. Veillette. "These antibodies could improve the function of the DNAM-1 protein, thereby improving the ability of NK cells to destroy . This type of therapy could have a significant impact on the next generation of cancer treatments."

Explore further: Researchers explain how our immune system kills abnormal blood cells

More information: Journal of Experimental Medicine, jem.rupress.org/content/early/ … em.20150792.abstract

Related Stories

Researchers explain how our immune system kills abnormal blood cells

April 8, 2014
A team of researchers at the IRCM, led by André Veillette, MD, explains how our immune system kills abnormal blood cells. Their discovery, recently published in the Journal of Experimental Medicine, could eventually lead ...

Researchers elucidate a molecular mechanism associated with an immune disorder

June 7, 2012
A team of researchers at the IRCM led by Dr. André Veillette made an important breakthrough in the field of immunology, which will be published online today by the scientific journal Immunity. The scientists explained ...

Inhibited Tyk2 retains anti-cancer activity

September 11, 2015
Tyrosine kinase 2 (Tyk2) is an enzyme involved in intracellular signalling and has an important role in activating the immune system. But enzymatically active Tyk2 can also promote excessive immune reactions and growth of ...

Study discovers negative regulator of natural killer cell maturation

May 6, 2015
A new study has identified a regulatory pathway in natural killer cells that inhibits their maturation and homing behavior. Natural killer cells are one of the body's first lines of defense against viruses and cancer. The ...

Scientists find way to make leukemia cells kill each other

October 19, 2015
Scientists at The Scripps Research Institute (TSRI) have found a way to change leukemia cells into leukemia-killing immune cells. The surprise finding could lead to a powerful new therapy for leukemia and possibly other cancers.

CytomX and MD Anderson Cancer Center enter into strategic collaboration for Probody-enabled CAR-NK cell therapies

November 5, 2015
CytomX Therapeutics, a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, today entered into a collaboration with The University of Texas MD Anderson Cancer Center to research ...

Recommended for you

African Americans face highest risk for multiple myeloma yet underrepresented in research

November 23, 2017
Though African-American men are three times more likely to be diagnosed with multiple myeloma, a type of blood cancer, most scientific research on the disease has been based on people of European descent, according to a study ...

Encouraging oxygen's assault on iron may offer new way to kill lung cancer cells

November 22, 2017
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers ...

One-size treatment for blood cancer probably doesn't fit all, researchers say

November 22, 2017
Though African-American men are three times more likely to be diagnosed with a blood cancer called multiple myeloma, most scientific research on the disease has been based on people of European descent, according to a study ...

One in four U.S. seniors with cancer has had it before

November 22, 2017
(HealthDay)—For a quarter of American seniors, a cancer diagnosis signals the return of an old foe, new research shows.

Combination immunotherapy targets cancer resistance

November 22, 2017
Cancer immunotherapy drugs have had notable but limited success because in many cases, tumors develop resistance to treatment. But researchers at Yale and Stanford have identified an experimental antibody that overcomes this ...

Researchers discover specific tumor environment that triggers cells to metastasize

November 21, 2017
A team of bioengineers and bioinformaticians at the University of California San Diego have discovered how the environment surrounding a tumor can trigger metastatic behavior in cancer cells. Specifically, when tumor cells ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.